Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Debt to Equity: 2016-2018

  • Niagen Bioscience's Debt to Equity fell 12.46% to $0.01 in Q4 2018 from the same period last year, while for Dec 2018 it was $0.01, marking a year-over-year decrease of 12.46%. This contributed to the annual value of $0.01 for FY2018, which is 12.46% down from last year.
  • Per Niagen Bioscience's latest filing, its Debt to Equity stood at $0.01 for Q4 2018, which was down 12.46% from $0.01 recorded in Q4 2017.
  • Niagen Bioscience's 5-year Debt to Equity high stood at $0.92 for Q1 2016, and its period low was $0.01 during Q4 2018.
  • Over the past 3 years, Niagen Bioscience's median Debt to Equity value was $0.02 (recorded in 2016), while the average stood at $0.24.
  • Data for Niagen Bioscience's Debt to Equity shows a maximum YoY crashed of 96.27% (in 2016) over the last 5 years.
  • Quarterly analysis of 3 years shows Niagen Bioscience's Debt to Equity stood at $0.03 in 2016, then tumbled by 83.30% to $0.01 in 2017, then fell by 12.46% to $0.01 in 2018.
  • Its Debt to Equity was $0.01 in Q4 2018, compared to $0.01 in Q4 2017 and $0.03 in Q4 2016.